PT  - JOURNAL ARTICLE
AU  - Stephen J. Assinder
AU  - Qihan Dong
AU  - Helena Mangs
AU  - Des R. Richardson
TI  - Pharmacological Targeting of the Integrated Protein Kinase B, Phosphatase and Tensin Homolog Deleted on Chromosome 10, and Transforming Growth Factor-β Pathways in Prostate Cancer
AID  - 10.1124/mol.108.053066
DP  - 2009 Mar 01
TA  - Molecular Pharmacology
PG  - 429--436
VI  - 75
IP  - 3
4099  - http://molpharm.aspetjournals.org/content/75/3/429.short
4100  - http://molpharm.aspetjournals.org/content/75/3/429.full
SO  - Mol Pharmacol2009 Mar 01; 75
AB  - Prostate cancer is a highly heterogenous disease in which a patient-tailored care program is much desired. Central to this goal is the development of novel targeted pharmacological interventions. To develop these treatment strategies, an understanding of the integration of cellular pathways involved in both tumorigenesis and tumor suppression is crucial. Of further interest are the events elicited by drug treatments that exploit the underlying molecular pathology in cancer. This review briefly describes the evidence that suggests integration of three established pathways: the tumorigenic phosphoinositide 3-kinase/protein kinase B (AKT) pathway, the tumor suppressive phosphatase and tensin homolog deleted on chromosome 10 pathway, and the tumor suppressive transforming growth factor-β pathway. More importantly, we discuss novel pharmaceutical agents that target key points of integration in these three pathways. These new therapeutic strategies include the use of agents that target iron to inhibit proliferation via multiple mechanisms and suppression of AKT by cytosolic phospholipase A2-α inhibitors. The American Society for Pharmacology and Experimental Therapeutics